Revolution Medicines
D

RVMD

Revolution Medicines income statement 2017–2026

0.00 USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
Revenue
—0.000.0011.58M35.38M29.39M42.98M50.04M20.17M0.00
Revenue growth
——-100.00%-67.27%+20.38%-31.62%-14.10%+148.16%——
Cost of revenue
—16.56M0.000.000.000.000.000.000.0026.59M
Gross profit
—-16.56M0.0011.58M35.38M29.39M42.98M50.04M20.17M-26.59M
Gross margin
———100.00%100.00%100.00%100.00%100.00%100.00%—
Research and development
1.45B978.68M592.23M423.14M253.07M186.95M132.25M91.76M51.08M26.59M
Selling, general and administrative
429.08M187.13M97.30M75.62M40.59M30.45M21.43M12.41M9.41M4.54M
Operating expenses
1.87B1.17B689.52M498.77M293.66M217.40M153.68M104.16M60.49M4.54M
-1.69B-1.18B-689.52M-487.19M-258.28M-188.01M-110.70M-54.12M-40.33M-31.13M
Operating margin
———-4,207.12%-730.01%-639.70%-257.54%-108.15%-200.00%—
Interest income
114.16M90.69M86.88M47.48M9.15M929.00K2.24M2.19M777.00K105.00K
Interest expense
81.72M24.23M—303.00K—12.00K71.00K106.00K116.00K103.00K
Other non-operating income
-187.76M51.07M88.68M47.29M9.15M917.00K2.17M2.08M-1.46M2.00K
Pretax income
-1.87B-1.13B-600.85M-439.89M-249.13M-187.09M-108.53M-52.04M-41.79M-31.13M
Income tax
—0.00-753.00K-3.52M-420.00K0.00-371.00K-4.37M0.00105.00K
-1.87B-1.13B-600.09M-436.37M-248.71M-187.09M-108.16M-47.66M-41.79M-31.13M
Net margin
———-3,768.28%-702.95%-636.58%-251.63%-95.25%-207.24%—
Basic shares
203.52M190.13M167.74M113.15M80.63M72.81M66.60M36.47M36.47M36.47M
Diluted shares
203.52M190.13M167.74M113.15M80.63M72.81M66.60M36.47M36.47M36.47M
Change in diluted shares
+11.02%+13.35%+48.24%+40.34%+10.74%+9.32%+82.60%0.00%0.00%—
EPS (basic)
-9.15-5.95-3.58-3.86-3.08-2.47-1.62-1.31-1.15-0.85
EPS (diluted)
-9.15-5.95-3.58-3.86-3.08-2.57-1.62-1.31-1.15-0.85
EBITDA
-1.77B-1.09B-589.02M-430.28M-239.47M-179.75M-101.91M-48.59M-39.91M-29.84M
EBITDA margin
———-3,715.71%-676.85%-611.59%-237.10%-97.10%-197.91%—
EBIT
-1.79B-1.11B-600.85M-439.59M-249.13M-187.08M-108.46M-51.93M-41.67M-31.02M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Revolution Medicines's income statement

Source: Financial Modeling PrepVerified against SEC filings